Antisense treatment against Ki‐67 mRNA inhibits proliferation and tumor growth in vitro and in vivo
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The Ki‐67 protein is tightly regulated and depends on the proliferative status of a cell. It is present in the nuclei of proliferating cells but absent in resting cells. Since transformation of malignant cells is frequently associated with high cell proliferation and since proliferation is tightly associated with the Ki‐67 protein labeling index, this antigen may represent a potential target for cancer therapy. In the present study we determined the ability of a phosphorothioate antisense oligodeoxyribonucleotide (ODN) targeted against Ki‐67 mRNA to inhibit tumor cell proliferation specifically in cell culture, in multicellular 3‐dimensional spheroids (MCS) and in subcutaneous murine tumor models. Antisense treatment of 1 myeloid and different epithelial tumor cell lines in suspension and monolayer culture, respectively, resulted in specific reduction of Ki‐67 mRNA and protein, inhibition of proliferation and increased apoptotic cell death. Multicellular human bladder carcinoma spheroids lost their 3‐dimensional structure and underwent cell death after incubation with antisense oligonucleotides. The growth of subcutaneous syngeneic prostatic (p = 0.05) and transitional cell tumors (p = 0.001) in immunocompetent mice was significantly inhibited in antisense‐treated animals. From these findings we conclude that antisense inhibition of Ki‐67 protein expression may be a rational approach in anticancer therapy. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., & Stein, H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1710 · Cited by 4,173
Self-citation
Cited by
Ki-67: more than a proliferation marker
Sun, X., & Kaufman, P. D. (2018) · Chromosoma · doi:10.1007/s00412-018-0659-8 · Cited by 963
Ki67 is a promising molecular target in the diagnosis of cancer (Review)
LI, L. T., JIANG, G., CHEN, Q., & ZHENG, J. N. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2914 · Cited by 859
Cell-Cycle Regulation Accounts for Variability in Ki-67 Expression Levels
Sobecki, M., Mrouj, K., Colinge, J., Gerbe, F., Jay, P., Krasinska, L., Dulic, V., & Fisher, D. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0707 · Cited by 375
The cell proliferation antigen Ki-67 organises heterochromatin
Sobecki, M., Mrouj, K., Camasses, A., Parisis, N., Nicolas, E., Llères, D., Gerbe, F., Prieto, S., Krasinska, L., David, A., et al. (2016) · eLife · doi:10.7554/elife.13722 · Cited by 362
Ki67 targeted strategies for cancer therapy
Yang, C., Zhang, J., Ding, M., Xu, K., Li, L., Mao, L., & Zheng, J. (2018) · Clinical and Translational Oncology · doi:10.1007/s12094-017-1774-3 · Cited by 254
Metadata
- Authors
- Kausch, I., Lingnau, A., Endl, E., Sellmann, K., Deinert, I., Ratliff, T. L., Jocham, D., Sczakiel, G., Gerdes, J., & Böhle, A.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2003-04-02
- Volume
- 105
- Issue
- 5
- Pages
- 710-716
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2005771621
- Cited by
- 88
- References
- 1
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antisense treatment against Ki‐67 mRNA inhibits proliferation and tumor growth in vitro and in vivo. https://app.cochat.ai/papers/10.1002/ijc.11111
- The paper
- Kausch, I., Lingnau, A., Endl, E., Sellmann, K., Deinert, I., Ratliff, T. L., Jocham, D., Sczakiel, G., Gerdes, J., & Böhle, A. (2003). Antisense treatment against Ki‐67 mRNA inhibits proliferation and tumor growth in vitro and in vivo. International Journal of Cancer. https://doi.org/10.1002/ijc.11111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.